The President of an American biosciences company has applauded the University of Leicester for its work into ground-breaking identification of new treatment for infectious hospital bugs.
Phil Young, from AmpliPhi Biosciences Corporation, also commented on his excitement at working with Dr Martha Clokie, the lead scientist at the university.
– Phil Young, CEO and President of AmpliPhi Biosciences Corporation
We are very excited about this partnership with Dr Clokie and the University of Leicester. Phage-based therapy has the potential to revolutionise the way C diff infections are treated in the clinic, in compliance with the regulatory frameworks already in place. We firmly believe that this collaboration may result in a treatment that could benefit patients, clinicians and health-care organisations alike.